PGNY vs TXG: fair value comparison
Progyny, Inc. and 10x Genomics, Inc. · Updated 2026-10-19
TXG has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, PGNY currently ranks higher by quality score.
| PGNY | TXG | |
|---|---|---|
| Verdict | Undervalued | No estimate yet |
| Last price | $26.86 | $69.86 |
| 12-month range | $16.30–$32.36 | $12.44–$97.74 |
| Rank by discount to fair value | #16 of 108 Healthcare | — |
| Rank by quality score | #43 of 301 Healthcare | #45 of 301 Healthcare |
| Quality grade | A | A |
| Leverage | Low | Low |
| Margin trend | Expanding | Stable |
| Revenue growth | Modest | Declining |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | Mixed |
| DCF cross-check | Undervalued | — |
| 52-week position | The upper-middle quarter | The upper-middle quarter |
Full single-stock breakdowns: PGNY fair value analysis · TXG fair value analysis